The Conundrum of Anticoagulation for Hospitalized Patients with Covid-19.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38320043.
- Also identified by DOI 10.1056/EVIDe2200329.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thrombosis in patients with coronavirus disease 2019 (Covid-19) is driven by complex interactions between immune, complement, fibrinolytic, endothelial, and coagulation systems.<sup>1</sup> In addition to venous thromboembolism (VTE), microthrombi have also been implicated in contributing to end-organ damage, such as acute respiratory distress syndrome and kidney dysfunction, as well as to overall mortality.<sup>1</sup> As available therapies, variants, and vaccines have evolved, so have reported rates of VTE attributable to Covid-19.
Medical subject headings
- COVID-19
- Venous Thromboembolism
- Thrombosis